Iloperidone (Fanapt) vs Perseris
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (Fanapt)
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Reported efficacy
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)
Result source: NCT00254202
Perseris
Rights held by Indivior Pharmaceuticals, Inc.; US product discontinued
NCT02109562 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.
Reported efficacy
Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162) (met)
Result source: NCT02109562
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Iloperidone (Fanapt) | Perseris |
|---|---|---|
| PANSS total, change | -12 vs -7.1−4.9 vs placeboNCT002542021 other result
| -16.5 vs -9.2−7.2 vs placeboNCT021095627 other results
|
| CGI-S, change | —Trial running · NCT06961968 | -0.1 vs -0.3+0.2 vs placeboNCT022038387 other results
|
| PANSS response | —Trial running · NCT06961968 | —Not reported |
| PSP, change | —Trial running · NCT06961968 | —Not reported |
| Relapse (% of patients) | —Trial running · NCT06961968 | —Not reported |
PANSS total, change
- Iloperidone (Fanapt)
- -12 vs -7.1−4.9 vs placeboNCT00254202
1 other result
- 1.1 vs 12.4 NCT01291511
- Perseris
- -16.5 vs -9.2−7.2 vs placeboNCT02109562
7 other results
- -15.4 vs -9.2 NCT02109562
- -1.2 vs -8.2 NCT02203838
- -1.2 vs -4.8 NCT02203838
- -9.4 vs -8.2 NCT02203838
- -2.4 vs -4.8 NCT02203838
- -10 vs -8.2 NCT02203838
- -8.3 vs -4.8 NCT02203838
CGI-S, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Perseris
- -0.1 vs -0.3+0.2 vs placeboNCT02203838
7 other results
- 0 vs -0.3 NCT02203838
- -0.9 vs -0.5 NCT02109562
- -0.9 vs -0.5 NCT02109562
- -0.4 vs -0.3 NCT02203838
- -0.1 vs -0.3 NCT02203838
- -0.3 vs -0.3 NCT02203838
- -0.2 vs -0.3 NCT02203838
PANSS response
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Perseris
- —Not reported
PSP, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Perseris
- —Not reported
Relapse (% of patients)
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Perseris
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Iloperidone (Fanapt): 4 of 4 rows · Perseris: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Iloperidone (Fanapt) | Perseris |
|---|---|---|
| Dropout rate | 34.6%a NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results51.3%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 30.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 31.5%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence 18.8%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 12.5%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 13.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 28.6%120 mgb NCT02109562 · Phase 3 · combination show 8 more results22.4%90 mg NCT02109562 · Phase 3 · combination 54.5%120 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 51.6%90 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 51.5%De Novo Participants NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 78.3%180 mg subcutaneous NCT03978832 · Phase 4 · registry result, not featured evidence 40%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results14.5%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 10.4%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 15%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 1.7%120 mgb NCT02109562 · Phase 3 · combination show 8 more results0%90 mg NCT02109562 · Phase 3 · combination 6.1%120 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.7%90 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 11.3%De Novo Participants NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 1.4%180 mg subcutaneous NCT03978832 · Phase 4 · registry result, not featured evidence —120 mg NCT01677377 · Phase 2 · registry result, not featured evidence —90 mg NCT01677377 · Phase 2 · registry result, not featured evidence —60 mg NCT01677377 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0.7%a NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results—Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 4%Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 2.7%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 14.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 7.1%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 0.9%120 mgb NCT02109562 · Phase 3 · combination show 8 more results0%90 mg NCT02109562 · Phase 3 · combination 9.1%120 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.7%90 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 6.1%De Novo Participants NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 4.3%180 mg subcutaneous NCT03978832 · Phase 4 · registry result, not featured evidence 6.7%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a headache 20.3% (placebo 19.7%) dizziness 17% (placebo 7.5%) sedation 12.7% (placebo 8.2%) NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 18 more resultsdizziness 11.6% (placebo 2.7%) somnolence 8.3% (placebo 0%) dry mouth 6.8% (placebo 0%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dizziness 2.6% (placebo 2.7%) headache 2% (placebo 3.3%) insomnia 2% (placebo 4.7%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dry mouth 17.9% dizziness 17.5% somnolence 14.2% NCT01207414 · Phase 4 · registry result, not featured evidence dizziness 22.3% dry mouth 20.8% insomnia 9.6% NCT01207414 · Phase 4 · registry result, not featured evidence 625 mg injection site pain 66.7% injection site induration 60% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 625 mg headache 20% nasal congestion 20% anxiety 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg injection site pain 60% injection site induration 26.7% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg nasal congestion 33.3% constipation 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg back pain 7.1% constipation 7.1% headache 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg insomnia 20% headache 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg constipation 14.3% headache 14.3% anxiety 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg headache 33.3% insomnia 33.3% dyspepsia 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg injection site pain 53.3% headache 26.7% nasal congestion 26.7% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg nasal congestion 40% headache 26.7% oropharyngeal pain 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg pruritus 50% throat irritation 50% upper respiratory tract infection 50% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg constipation 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg blood creatine phosphokinase increased 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg dizziness 50% headache 50% agitation 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence | 120 mgb injection site pain 22.2% (placebo 19.5%) headache 15.4% (placebo 23.7%) weight increased 12.8% (placebo 3.4%) NCT02109562 · Phase 3 · combination show 8 more results90 mg headache 17.4% (placebo 23.7%) injection site pain 15.7% (placebo 19.5%) weight increased 13% (placebo 3.4%) NCT02109562 · Phase 3 · combination 120 mg injection site pain 21.2% (placebo 7.1%) injection site induration 9.1% (placebo 0%) injection site nodule 9.1% (placebo 3.6%) NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 90 mg headache 12.9% (placebo 0%) injection site pain 12.9% (placebo 7.1%) insomnia 12.9% (placebo 3.6%) NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 weight increased 14.7% (placebo 3.6%) injection site pain 12.7% (placebo 7.1%) injection site nodule 7.1% (placebo 3.6%) NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 180 mg subcutaneous upper respiratory tract infection 13% blood prolactin increased 8.7% decreased appetite 8.7% NCT03978832 · Phase 4 · registry result, not featured evidence 120 mg cough 20% dyspepsia 20% weight increased 20% NCT01677377 · Phase 2 · registry result, not featured evidence 90 mg weight increased 33.3% headache 20% dyspepsia 13.3% NCT01677377 · Phase 2 · registry result, not featured evidence 60 mg weight increased 26.7% headache 20% rash 20% NCT01677377 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 21 of these studies.
- bPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Iloperidone (Fanapt)
show 1 more result
show 3 more results
Perseris
show 7 more results
show 2 more results
show 2 more results
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Perseris's landscape